Types of diseases dupilumab/dalbitux are used to treat

Dupilumab (dupilumab) is an innovative biological agent that mainly exerts its therapeutic effects by antagonizing interleukin-4 receptor α. The drug has been approved by many countries for the treatment of a variety of immune-related diseases, especially in patients who have shown significant efficacy in the treatment of patients who have failed to respond to traditional treatment options.

First, dupilumab is widely used to treat atopic dermatitis , especially in adult and pediatric patients 6 months of age and older. These patients have moderate to severe atopic dermatitis that cannot be effectively controlled by traditional topical treatments, or topical treatments are used inappropriately or inappropriately. At this time, dupilumab may be used as a standalone treatment or in combination with topical corticosteroids to provide more effective control of skin inflammation.

Secondly, dupilumab also plays an important role in the treatment of asthma. It is indicated as add-on therapy in patients 6 years of age and older, particularly those with moderate to severe asthma with eosinophil-related features. For patients who rely on oral corticosteroids to control symptoms, dupilumab offers a more targeted treatment option. It should be noted that it is not indicated for the relief of acute bronchospasm or the treatment of status asthmaticus.

Duplimumab also has a significant effect in the treatment of chronic sinusitis. It is indicated for patients 12 years of age and older with chronic sinusitis associated with nasal polyps, especially those whose symptoms cannot be controlled by conventional treatments. As an additional maintenance treatment drug, this drug can effectively reduce patients' symptoms and improve their quality of life.

In addition, dupilumab is also used to treat eosinophilic esophagitis in patients one year old and older and weighing at least 15 kg. Eosinophilic esophagitis is an immune-mediated esophageal disease that usually manifests as an inflammatory response in the esophagus. Dupilumab can help these patients reduce symptoms and improve esophageal function.

In dermatology, dupilumab is also approved for the treatment of prurigo nodularis. This disease mainly manifests as nodular itching of the skin, which brings great trouble to patients' lives. Through treatment with dupilumab, the patient's symptoms can be effectively relieved.

For chronic obstructive pulmonary disease (COPD), dupilumab can also play an adjuvant therapeutic role. It is particularly useful in poorly controlled adult patients with an eosinophilic phenotype. Although it cannot be used for the relief of acute bronchospasm, as long-term maintenance treatment it can help improve symptoms and reduce the risk of exacerbations.

Finally, dupilumab is also used to treat chronic spontaneous urticaria. Such patients often have symptoms that persist despite conventional antihistamine treatment. The use of dupilumab can effectively control their allergic reactions and relieve skin itching and other related symptoms.

Overall, injectable treatment with dupilumab was well tolerated and resulted in high treatment compliance in most patients. Although injection therapy may cause some inconvenience to some patients, considering the efficacy and safety of the drug, this treatment method is worth choosing for many patients.

Reference materials:https://www.dupixent.com/